Author: Shapira, Assaf; Benhar, Itai
Title: Toxin-Based Therapeutic Approaches Document date: 2010_10_28
ID: 00cf294x_26
Snippet: Targeting CD22 and CD19: RFB4-dgA and HD37-dgA CD22 and CD19 are cell surface glycoproteins expressed on normal and malignant B cells [306] [307] [308] [309] . For targeting B-cell lymphoma cells, the anti CD22 monoclonal antibody RFB4 [190, 310] and the anti CD19 monoclonal antibody HD37 [311] were conjugated to dgA. In a Phase I clinical trial with the immunotoxin RFB4-dgA (IMTOX-22), five of 24 evaluable patients with B-cell lymphoma showed a .....
Document: Targeting CD22 and CD19: RFB4-dgA and HD37-dgA CD22 and CD19 are cell surface glycoproteins expressed on normal and malignant B cells [306] [307] [308] [309] . For targeting B-cell lymphoma cells, the anti CD22 monoclonal antibody RFB4 [190, 310] and the anti CD19 monoclonal antibody HD37 [311] were conjugated to dgA. In a Phase I clinical trial with the immunotoxin RFB4-dgA (IMTOX-22), five of 24 evaluable patients with B-cell lymphoma showed a partial response and one showed a complete response. Similar results were obtained when the drug was administrated as a continuous infusion instead of intermittent bolus [67, 312] . Partial and complete responses were also obtained in a Phase I trial on patients with non-Hodgkin's B-cell lymphoma treated with the immunotoxin HD37-dgA (IMTOX-19) [69] . Vascular leak syndrome (VLS) was a common dose-related toxicity in these studies.
Search related documents:
Co phrase search for related documents- cell surface and complete partial response: 1, 2, 3
- cell surface and complete response: 1, 2, 3, 4, 5
- cell surface and monoclonal antibody: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53
- cell surface and partial response: 1, 2, 3
- cell surface and similar result: 1, 2, 3, 4
- cell surface glycoprotein and clinical trial: 1
- cell surface glycoprotein and monoclonal antibody: 1, 2, 3, 4
- clinical trial and complete partial response: 1, 2, 3, 4, 5, 6, 7, 8
- clinical trial and complete response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- clinical trial and continuous infusion: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
Co phrase search for related documents, hyperlinks ordered by date